Panfeng Tan
Publications by Year
Research Areas
Gastric Cancer Management and Outcomes, Gastrointestinal Tumor Research and Treatment, Pancreatic and Hepatic Oncology Research, Lung Cancer Research Studies, Neuroendocrine Tumor Research Advances
Most-Cited Works
- → Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases(2022)51 cited
- → Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial(2024)29 cited
- → Preliminary results of a phase 1b study of fruquintinib plus sintilimab in advanced colorectal cancer.(2021)21 cited
- → Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial(2024)20 cited
- → Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer(2024)15 cited
- → Surufatinib in combination with toripalimab in patients with advanced neuroendocrine carcinoma: Results from a multicenter, open-label, single-arm, phase II trial.(2021)11 cited
- → 1519P Fruquintinib plus sintilimab in patients (pts) with either treatment-naïve or previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results from a multicenter, single-arm phase II study(2023)4 cited
- → Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial(2025)3 cited
- → Oral Celecoxib Versus Oral Diclofenac for Postperineal Repair Analgesia after Spontaneous Vaginal Birth: A Randomized Trial(2008)2 cited
- → Phase II trial of surufatinib plus toripalimab for disease progression after first-line chemotherapy with platinum and fluoropyrimidine in advanced gastric or gastroesophageal junction adenocarcinoma.(2021)1 cited